Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Novavax ( (NVAX) ) just unveiled an announcement.
On May 16, 2025, Novavax announced that the FDA approved its Biologics License Application for Nuvaxovid™, a COVID-19 vaccine for adults 65 and older and individuals 12-64 with high-risk conditions. This approval triggered a $175 million milestone payment from Sanofi Pasteur Inc. and requires a new Phase 4 trial for individuals aged 50-64 without high-risk conditions. Novavax plans to deliver the 2025-2026 vaccine formula in the U.S. this fall, pending FDA strain recommendations.
The most recent analyst rating on (NVAX) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Novavax stock, see the NVAX Stock Forecast page.
Spark’s Take on NVAX Stock
According to Spark, TipRanks’ AI Analyst, NVAX is a Neutral.
Novavax presents a mixed investment case. The company has demonstrated strong revenue growth and profitability improvements, yet its financial stability is undermined by high leverage and negative cash flows. The undervaluation based on P/E ratio offers potential upside, but the bearish technical indicators suggest caution. Strategic partnerships and cost reductions are positive, but regulatory and market penetration challenges pose risks.
To see Spark’s full report on NVAX stock, click here.
More about Novavax
Novavax, Inc. operates in the biotechnology industry, focusing on the development and commercialization of vaccines to prevent serious infectious diseases. The company is known for its work on vaccines for COVID-19, with a market focus on providing immunization solutions for various age groups and individuals with underlying health conditions.
Average Trading Volume: 6,701,452
Technical Sentiment Signal: Sell
Current Market Cap: $1.09B
See more data about NVAX stock on TipRanks’ Stock Analysis page.